联合疗法-话题@MedSci

#联合疗法#

64篇内容 | 2261人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1646997, encodeId=4b00164699e99, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）, objectType=article, longId=206596, objectId=62c62065968a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62c62065968a, replyNumber=0, likeNumber=61, createdTime=2021-07-28, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62c62065968a, moduleTitle=J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62c62065968a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646987, encodeId=8adb164698eac, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=西奈山索伦托合作开发针对新冠病毒COVID-19的三抗体联合疗法COVI-SHIELD, objectType=article, longId=193859, objectId=b66d1938590a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b66d1938590a, replyNumber=0, likeNumber=72, createdTime=2020-05-10, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b66d1938590a, moduleTitle=西奈山索伦托合作开发针对新冠病毒COVID-19的三抗体联合疗法COVI-SHIELD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b66d1938590a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646988, encodeId=eaff164698860, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Lancet Oncol：派姆单抗联合疗法一线治疗HER2阳性转移性食管胃癌, objectType=article, longId=194729, objectId=8973194e294c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8973194e294c, replyNumber=0, likeNumber=72, createdTime=2021-04-21, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8973194e294c, moduleTitle=Lancet Oncol：派姆单抗联合疗法一线治疗HER2阳性转移性食管胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8973194e294c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646996, encodeId=128c164699639, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=双特异性抗体KN026与KN046联合疗法获美国FDA孤儿药资格认定，用于治疗胃癌及胃食管连接部癌, objectType=article, longId=204839, objectId=18592048396e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18592048396e, replyNumber=0, likeNumber=67, createdTime=2021-03-31, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18592048396e, moduleTitle=双特异性抗体KN026与KN046联合疗法获美国FDA孤儿药资格认定，用于治疗胃癌及胃食管连接部癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18592048396e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646991, encodeId=cb62164699108, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Lancet Oncol：奥英妥珠单抗-DHAP联合疗法治疗套细胞淋巴瘤, objectType=article, longId=201135, objectId=43c4201135f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43c4201135f9, replyNumber=0, likeNumber=70, createdTime=2021-02-11, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43c4201135f9, moduleTitle=Lancet Oncol：奥英妥珠单抗-DHAP联合疗法治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43c4201135f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646984, encodeId=ff851646984b5, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Lancet：青蒿素为基础的三重联合疗法治疗耐药性恶性疟, objectType=article, longId=189921, objectId=2743189921b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2743189921b5, replyNumber=0, likeNumber=65, createdTime=2021-02-04, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2743189921b5, moduleTitle=Lancet：青蒿素为基础的三重联合疗法治疗耐药性恶性疟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2743189921b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646994, encodeId=c1db164699463, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败, objectType=article, longId=201995, objectId=a7e920199565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7e920199565, replyNumber=0, likeNumber=71, createdTime=2021-06-09, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7e920199565, moduleTitle=免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7e920199565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646985, encodeId=91af164698522, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, objectType=article, longId=190017, objectId=0f0519001e6d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0519001e6d, replyNumber=0, likeNumber=59, createdTime=2020-06-02, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0519001e6d, moduleTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f0519001e6d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646992, encodeId=771f164699281, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=礼来公布中和抗体联合疗法全新数据！向FDA提交紧急使用授权申请, objectType=article, longId=201862, objectId=fb8b201862d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb8b201862d6, replyNumber=0, likeNumber=71, createdTime=2020-12-15, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb8b201862d6, moduleTitle=礼来公布中和抗体联合疗法全新数据！向FDA提交紧急使用授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb8b201862d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646990, encodeId=428116469906b, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Sci Rep：来氟米特单药治疗类风湿性关节炎与联合疗法的比较 , objectType=article, longId=198335, objectId=666e198335c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=666e198335c9, replyNumber=0, likeNumber=71, createdTime=2021-02-26, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=666e198335c9, moduleTitle=Sci Rep：来氟米特单药治疗类风湿性关节炎与联合疗法的比较 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=666e198335c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646980, encodeId=54ab16469803f, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果, objectType=article, longId=180608, objectId=b0ed180608a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0ed180608a6, replyNumber=0, likeNumber=57, createdTime=2020-01-07, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0ed180608a6, moduleTitle=诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0ed180608a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646982, encodeId=c391164698209, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌, objectType=article, longId=185337, objectId=697318533ec4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=697318533ec4, replyNumber=0, likeNumber=60, createdTime=2020-05-20, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=697318533ec4, moduleTitle=Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=697318533ec4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646989, encodeId=eed916469892a, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=免疫治疗耐药？新联合疗法，有望克服PD-1免疫疗法耐药, objectType=article, longId=195305, objectId=e6621953051a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6621953051a, replyNumber=0, likeNumber=73, createdTime=2021-04-16, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6621953051a, moduleTitle=免疫治疗耐药？新联合疗法，有望克服PD-1免疫疗法耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6621953051a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646986, encodeId=0e8316469861d, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期, objectType=article, longId=193392, objectId=a9c11933925d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9c11933925d, replyNumber=0, likeNumber=64, createdTime=2021-03-13, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9c11933925d, moduleTitle=Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9c11933925d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646981, encodeId=5e7f164698199, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=罗氏T+A免疫联合疗法研究获历史性突破，晚期肝癌患者总生存大幅延长, objectType=article, longId=183619, objectId=3a94183619a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a94183619a8, replyNumber=0, likeNumber=93, createdTime=2020-01-16, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a94183619a8, moduleTitle=罗氏T+A免疫联合疗法研究获历史性突破，晚期肝癌患者总生存大幅延长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a94183619a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646976, encodeId=6f1516469e658, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=鼎航医药获8000万美元B轮融资，专注全球肿瘤免疫联合疗法, objectType=article, longId=168231, objectId=9a9916823111, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a9916823111, replyNumber=0, likeNumber=58, createdTime=2020-04-16, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a9916823111, moduleTitle=鼎航医药获8000万美元B轮融资，专注全球肿瘤免疫联合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9916823111)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646983, encodeId=5052164698302, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Lancet：Daratumumab联合疗法用于改善多发性骨髓瘤患者总生存期, objectType=article, longId=186076, objectId=871f1860e69e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=871f1860e69e, replyNumber=0, likeNumber=0, createdTime=2020-07-07, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=871f1860e69e, moduleTitle=Lancet：Daratumumab联合疗法用于改善多发性骨髓瘤患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=871f1860e69e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646975, encodeId=c1ed16469e5b5, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=诺华的吸入型联合疗法QMF149治疗哮喘III期试验达到实验终点, objectType=article, longId=167489, objectId=a85316e489c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a85316e489c3, replyNumber=0, likeNumber=73, createdTime=2020-03-30, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a85316e489c3, moduleTitle=诺华的吸入型联合疗法QMF149治疗哮喘III期试验达到实验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a85316e489c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646974, encodeId=3d3e16469e418, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=AP&T：优化的英夫利昔单抗疗法与联合疗法在治疗炎症性肠病中同样有效, objectType=article, longId=164335, objectId=610116433568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=610116433568, replyNumber=0, likeNumber=82, createdTime=2019-12-25, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=610116433568, moduleTitle=AP&T：优化的英夫利昔单抗疗法与联合疗法在治疗炎症性肠病中同样有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=610116433568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646979, encodeId=d76516469e9c5, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤, objectType=article, longId=180138, objectId=16d3180138ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d3180138ee, replyNumber=0, likeNumber=58, createdTime=2020-02-25, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d3180138ee, moduleTitle=美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d3180138ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合疗法

2020-05-29

wincls (审核中...)

前往app查看评论内容

#联合疗法#

J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）

2021-07-28

wincls (审核中...)

前往app查看评论内容

#联合疗法#

西奈山索伦托合作开发针对新冠病毒COVID-19的三抗体联合疗法COVI-SHIELD

2020-05-10

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Lancet Oncol：派姆单抗联合疗法一线治疗HER2阳性转移性食管胃癌

2021-04-21

wincls (审核中...)

前往app查看评论内容

#联合疗法#

双特异性抗体KN026与KN046联合疗法获美国FDA孤儿药资格认定，用于治疗胃癌及胃食管连接部癌

2021-03-31

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Lancet Oncol：奥英妥珠单抗-DHAP联合疗法治疗套细胞淋巴瘤

2021-02-11

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Lancet：青蒿素为基础的三重联合疗法治疗耐药性恶性疟

2021-02-04

wincls (审核中...)

前往app查看评论内容

#联合疗法#

免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败

2021-06-09

wincls (审核中...)

前往app查看评论内容

#联合疗法#

BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病

2020-06-02

wincls (审核中...)

前往app查看评论内容

#联合疗法#

礼来公布中和抗体联合疗法全新数据！向FDA提交紧急使用授权申请

2020-12-15

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Sci Rep：来氟米特单药治疗类风湿性关节炎与联合疗法的比较

2021-02-26

wincls (审核中...)

前往app查看评论内容

#联合疗法#

诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果

2020-01-07

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌

2020-05-20

wincls (审核中...)

前往app查看评论内容

#联合疗法#

免疫治疗耐药？新联合疗法，有望克服PD-1免疫疗法耐药

2021-04-16

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期

2021-03-13

wincls (审核中...)

前往app查看评论内容

#联合疗法#

罗氏T+A免疫联合疗法研究获历史性突破，晚期肝癌患者总生存大幅延长

2020-01-16

wincls (审核中...)

前往app查看评论内容

#联合疗法#

鼎航医药获8000万美元B轮融资，专注全球肿瘤免疫联合疗法

2020-04-16

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Lancet：Daratumumab联合疗法用于改善多发性骨髓瘤患者总生存期

2020-07-07

wincls (审核中...)

前往app查看评论内容

#联合疗法#

诺华的吸入型联合疗法QMF149治疗哮喘III期试验达到实验终点

2020-03-30

wincls (审核中...)

前往app查看评论内容

#联合疗法#

AP&T：优化的英夫利昔单抗疗法与联合疗法在治疗炎症性肠病中同样有效

2019-12-25

wincls (审核中...)

前往app查看评论内容

#联合疗法#

美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤

2020-02-25

科室
- - 订阅+
  - 更多科室
工具
服务